Description: WuXi AppTec Co., Ltd. provides research and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through, China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CMO/CDMO Services, and Other segments. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Home Page: www.wuxiapptec.com
288 Fute Zhong Road
Shanghai,
200131
China
Phone:
86 21 5046 1111
Officers
| Name | Title |
|---|---|
| Dr. Ge Li Ph.D. | Co-Founder, Chairman, President & CEO |
| Dr. Minzhang Chen Ph.D. | Co-CEO & Executive Director |
| Dr. Qing Yang Ph.D. | Co-CEO & Executive Director |
| Dr. Edward Hu M.B.A. | Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU |
| Ms. Ming Shi | Senior VP & CFO |
| Mr. Zhaohui Zhang | COO of China, Executive VP & Executive Director |
| Mr. Yuanzhou Zhang | Joint Company Secretary |
| Mr. Ruijia Tang | IR Director |
| Dr. Jingchao Dong Ph.D. | Senior VP & Head of RCS |
| Mr. Tao Guo Ph.D. | Senior VP and Head of RCS BD&IPM |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 13.587 |
|---|---|
| Trailing PE: | 19.7105 |
| Price-to-Book MRQ: | 2.8501 |
| Price-to-Sales TTM: | 0.5918 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 41116 |